…
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-05-31 |
| Income before tax | -1.45M | -3.12M | -2.71M | -0.95M | -0.27M |
| Net income | -1.59M | -3.12M | -2.71M | -0.95M | -0.27M |
| Selling general administrative | 0.80M | 0.68M | 2.67M | 1.54M | 0.35M |
| Selling and marketing expenses | - | 1.40M | 0.01M | 0.64M | 0.28M |
| Gross profit | 0.00M | -0.13M | -0.05M | 0.06M | 0.52M |
| Reconciled depreciation | 0.00M | 0.18M | 0.11M | - | 0.11M |
| Ebit | - | -3.12M | -2.70M | -0.95M | -0.44M |
| Ebitda | -1.38M | -2.94M | -2.59M | -0.90M | -0.32M |
| Depreciation and amortization | - | 0.18M | 0.11M | 0.05M | 0.12M |
| Operating income | -1.38M | -3.12M | -2.71M | -0.84M | -0.11M |
| Other operating expenses | 1.38M | 3.70M | 3.25M | 1.06M | 0.80M |
| Interest expense | 0.06M | 0.00M | 0.00M | 0.01M | 0.01M |
| Tax provision | 0.00M | 0.00M | 0.00M | - | 0.00M |
| Net interest income | -0.06M | -0.00M | -0.00M | - | -0.01M |
| Income tax expense | - | - | - | - | -0.00M |
| Total revenue | 0.00M | 0.59M | 0.54M | 0.22M | 0.69M |
| Total operating expenses | 1.38M | 3.26M | 2.66M | 0.90M | 0.63M |
| Cost of revenue | 0.00M | 0.45M | 0.59M | 0.16M | 0.17M |
| Total other income expense net | -0.06M | -0.00M | -0.00M | -0.11M | -0.16M |
| Net income from continuing ops | -1.45M | -3.12M | -2.71M | - | -0.45M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-05-31 |
| Total assets | 3.20M | 2.43M | 4.94M | 3.13M | 2.77M |
| Intangible assets | - | 2.07M | 2.07M | 2.07M | 2.07M |
| Other current assets | 0.06M | 0.04M | 0.33M | 0.12M | - |
| Total liab | 0.12M | 0.41M | 0.39M | 2.32M | 1.22M |
| Total stockholder equity | 3.08M | 2.03M | 4.55M | 0.81M | 1.54M |
| Other current liab | 0.04M | 0.12M | 0.14M | 0.53M | 0.26M |
| Common stock | 2.23M | 0.04M | 0.04M | 0.01M | 0.01M |
| Capital stock | 2.23M | 0.04M | 0.04M | 0.01M | - |
| Retained earnings | -10.55M | -8.96M | -5.84M | -3.14M | -2.19M |
| Cash | 0.76M | 0.15M | 1.64M | 0.60M | 0.21M |
| Total current liabilities | 0.12M | 0.39M | 0.37M | 2.32M | 1.22M |
| Current deferred revenue | - | 0.09M | 0.04M | - | - |
| Net debt | -0.76M | -0.12M | -1.62M | 0.35M | 0.45M |
| Short term debt | - | 0.01M | 0.00M | 0.95M | 0.68M |
| Short long term debt | - | - | 0.00M | 0.96M | - |
| Short long term debt total | - | 0.03M | 0.02M | 0.95M | 0.65M |
| Other stockholder equity | 11.41M | 14.00M | 7.86M | 3.94M | 3.43M |
| Total current assets | 0.81M | 0.31M | 2.16M | 0.74M | 0.26M |
| Net receivables | 0.00M | 0.07M | 0.04M | 0.04M | 0.06M |
| Inventory | 0.00M | 0.05M | 0.19M | 0.00M | - |
| Accounts payable | 0.08M | 0.16M | 0.18M | 0.84M | 0.28M |
| Accumulated other comprehensive income | - | 3.95M | 3.36M | 3.00M | - |
| Non currrent assets other | 0.30M | 0.01M | 0.01M | 0.01M | 0.01M |
| Non current assets total | 2.39M | 2.12M | 2.78M | 2.39M | 2.50M |
| Capital lease obligations | 0.00M | 0.03M | 0.02M | 0.00M | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-05-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2021-05-31 |
| Total cashflows from investing activities | -0.34M | -0.23M | -0.72M | -0.00M | -0.02M |
| Net borrowings | 0.20M | 0.00M | 0.00M | - | 0.20M |
| Total cash from financing activities | 2.08M | - | 4.13M | 0.80M | 0.20M |
| Net income | -1.59M | -3.12M | -2.71M | -0.95M | -0.27M |
| Change in cash | 0.60M | -1.49M | 1.04M | 0.39M | 0.12M |
| Begin period cash flow | 0.15M | 1.64M | 0.60M | 0.21M | 0.09M |
| End period cash flow | 0.76M | 0.15M | 1.64M | 0.60M | 0.21M |
| Total cash from operating activities | -1.13M | -1.24M | -2.36M | -0.25M | 0.00M |
| Issuance of capital stock | 1.92M | 0.00M | 4.47M | - | 0.00M |
| Depreciation | 0.00M | 0.18M | 0.11M | 0.05M | 0.12M |
| Other cashflows from investing activities | -0.32M | - | - | - | - |
| Change to inventory | 0.00M | 0.01M | -0.19M | - | - |
| Change to account receivables | 0.03M | 0.01M | 0.04M | -0.06M | -0.04M |
| Other cashflows from financing activities | -0.04M | - | -0.34M | 0.80M | - |
| Capital expenditures | 0.00M | 0.23M | 0.72M | 0.00M | 0.02M |
| Change in working capital | -0.03M | 0.41M | -0.64M | 0.65M | 0.16M |
| Stock based compensation | 0.32M | 0.37M | 0.86M | - | - |
| Other non cash items | 0.17M | 0.92M | 1.74M | -0.55M | -0.01M |
| Free cash flow | -1.13M | -1.47M | -3.08M | -0.26M | -0.01M |
Sector: Industrials Industry: Specialty Industrial Machinery
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SVNS Solvonis Therapeutics plc |
-0.00 4.21% |
0.09 | - | - | 9.59 | 2.55 | 10.28 | -19.66 |
| MYSE Ming Yang Smart Energy Group Ltd. GDR |
- -% |
7.20 | 0.81 | 12.08 | 0.00 | 0.81 | 0.11 | 2.09 |
| WEIR Weir Group PLC |
22.00 0.85% |
2598.00 | 32.23 | 20.92 | 3.10 | 3.93 | 3.42 | 15.64 |
| SMIN Smiths Group PLC |
13.00 0.49% |
2679.00 | 33.28 | 14.84 | 2.58 | 4.36 | 2.78 | 14.32 |
| IMI IMI PLC |
-8.00 0.28% |
2862.00 | 22.27 | 18.59 | 2.92 | 5.70 | 2.97 | 12.23 |
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Anthony James Tennyson | CEO & Executive Director | 1976 |
| Mr. Victor Bolduev | Founder | 1957 |
| Mr. Ryan Paul Neates | Chief Financial Officer | 1991 |
| Prof. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D. | Chief Scientific Advisor | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.